* Derma Sciences Inc., of Princeton, N.J., named Stephen Wills chief financial officer and vice president of finance.

* Endorex Corp., of Chicago, appointed to its board of directors Richard Dunning, president and CEO of VIMRX Pharmaceuticals Inc., of Wilmington, Del., and H. Laurence Shaw, chairman, president and CEO of Pacific Pharmaceuticals Inc.

* Gamera Bioscience Corp., of Medford, Mass., named Richard Eagling president.

* Genetronics Biomedical Ltd., of Vancouver, British Columbia, named to its board of directors Wayne Schnarr, vice president and director of BioCatalyst Yorkton Inc., of Toronto.

* Genelabs Technologies Inc., of Redwood City, Calif., appointed Marc Gurwith vice president of drug development and chief medical officer.

* GelTex Pharmaceuticals Inc., of Waltham, Mass., made the following appointments: Steven Burke, vice president of clinical research; Jeffrey Klinger, vice president of infectious diseases; Cynthia Arbeeny, director of lipid research; and Lisa Martin, director of human resources.

* Gliatech Inc., of Cleveland, appointed Frank Guglielmo director of marketing.

* ICAgen Inc., of Research Triangle Park, N.C., appointed to its board of directors Dennis Gillings, chairman and CEO of Quintiles Transnational Corp., of Research Triangle Park, N.C.

* ImmuDyne Inc., of Houston, named John Joshua director of the company and Robert Nakamura chairman of the board.

* Integrated Neuroscience Consortium Inc., of San Diego, named George Pache vice president of finance and chief financial officer.

* IntraBiotics Pharmaceuticals Inc. appointed Kathleen Dumas senior director of regulatory affairs.

* Isis Pharmaceuticals Inc., of Carlsbad, Calif., appointed to its board of directors Burkhard Blank, head of international project management at Boehringer Ingelheim G.m.b.H., of Ingelheim, Germany.

* Metra Biosystems Inc., of Mountain View, Calif., named Debby Dean vice president of human resources and administration.

* NeoTherapeutics Inc., of Irvine, Calif., appointed Scott Weiland director of regulatory affairs.

* NitroMed Inc., of Boston, named Michael Loberg chief executive officer.

* Pangea Systems Inc., of Oakland, Calif., appointed to its scientific advisory board Phil Green, associate professor of molecular biotechnology at the University of Washington, in Seattle.

* Peptimmune Inc., of Cambridge, Mass., appointed James Rasmussen vice president of research and development and chief scientific officer.

* Perkin-Elmer Corp., of Norwalk, Conn., named Dennis Winger senior vice president, chief financial officer and treasurer.

* Pharmaceutical Product Development Inc., of Wilmington, N.C., appointed David Williams vice president of human resources and Paul Ossi vice president of product development for PPD Pharmaco, a subsidiary.

* PLC Systems Inc., of Franklin, Mass., named William Dow president and chief executive officer.

* Quintiles Transnational Corp., of Research Triangle Park, N.C., appointed Virginia Weldon to the board of directors.

* SangStat Medical Corp., of Menlo Park, Calif., appointed Martin Rosendale senior vice president of U.S. sales and distribution.

* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., named Joseph Vallner vice president and chairman of the operating committee.

* SYNSORB Biotech Inc., of Calgary, Canada, appointed Brad Thompson chairman of the board and CEO.

* TheraTech Inc., of Salt Lake City, appointed Eric Aguiar director of business planning and financial analysis.

* Transkaryotic Therapies Inc., of Cambridge, Mass., named Beverly Holley director of corporate communications.